SGLT-2 Inhibitors & GLP-1 RAs in CV Risk: What Have We Learned From CVOTs in T2DM? Is MACE Independent of Glucose Lowering?

271 views
January 15, 2021
Comments 0
Login to view comments. Click here to Login